NAPS2 Neuroimaging Core

NAPS2 神经影像核心

• 批准号: 10674049
• 负责人: KEJAL KANTARCI
• 金额: $ 53.77万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-01 至 2027-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10674049
• 关键词: 3-Dimensional; Alzheimer' s Disease; Alzheimer' s disease related dementia; American; Atrophic; Brain Stem; Brain imaging; Cell Nucleus; Clinical; Clinical Data; Clinical Research; Collaborations; Collection; Communities; Confidentiality of Patient Information; Corpus striatum structure; Cross-Sectional Studies; Data; Data Collection; Data Set; Dementia with Lewy Bodies; Diffusion; Diffusion Magnetic Resonance Imaging; Disease; Disease Progression; Drug Delivery Systems; Ensure; Foundations; Functional Magnetic Resonance Imaging; Functional disorder; Funding; Future; Genetic; Goals; Image; Imaging Device; Investigation; Iron; Laboratories; Language; Longitudinal Studies; Magnetic Resonance Imaging; Maintenance; Maps; Measurement; Measures; Methods; Monitor; Multiple System Atrophy; Nerve Degeneration; Neurodegenerative Disorders; Office of Administrative Management; Outcome; Parasomnias; Parkinson Disease; Participant; Patients; Pattern; Play; Predisposition; Process; Protocols documentation; Quality Control; REM Sleep Behavior Disorder; Radionuclide Imaging; Reproducibility; Research; Research Personnel; Resolution; Resources; Rest; Role; Scanning; Site; Standardization; Substantia nigra structure; Symptoms; Techniques; Testing; Thick; Time; United States National Institutes of Health; Work; basal forebrain; biomarker identification; candidate marker; cerebral atrophy; clinical care; data management; data sharing; dopamine system; experience; genetic information; high risk; image processing; imaging modality; imaging study; innovation; interest; locus ceruleus structure; longitudinal analysis; multimodality; neuroimaging; neuroimaging marker; neuromelanin; neuroprotection; pars compacta; programs; progression marker; prospective; single photon emission computed tomography; sound; synucleinopathy; targeted biomarker; targeted treatment; trial design; uptake; web site

ABSTRACT: NAPS2 NEUROIMAGING CORE The Neuroimaging Core of the North American Prodromal Synucleinopathy Consortium on RBD, Stage 2 (NAPS2) will ensure that state-of-the-art techniques are applied and that innovative analytic techniques are used. The Neuroimaging Core will be directed by leaders in brain imaging in neurodegenerative diseases with extensive experience supporting the imaging needs of multi-site projects. Many of the Core leaders have collaborated with NAPS investigators on prior research in RBD and synucleinopathies. The prior experience and collaborations within the Neuroimaging Core team will ensure a smooth transition of imaging support for NAPS2. Prior imaging studies of RBD are few and have generally been small, retrospective, or single-site investigations. We provide preliminary data to support all of the imaging modalities that will be utilized in the protocol and demonstrate the soundness of the methods proposed. We will prospectively collect and evaluate multimodal MRI and DaTscan imaging data in over 300 participants with RBD longitudinally, at two time points, with innovative methods to support the Project and advance the field. There are several innovative aspects of this Core, including the use of: 1) multi-shell and multi-band imaging acquisition protocols for collection of high resolution dMRI and rs-fMRI data in reasonable acquisition time, harmonized across multiple sites, 2) quantification of iron load with multi-echo gradient echo (GRE) MRI using quantitative susceptibility mapping and R2* relaxometry, 3) quantification of neuromelanin volume in locus coeruleus and substantia nigra pars compacta using a magnetization transfer contrast neuromelanin-sensitive MRI (NM-MRI) approach with automated image processing and high reproducibility, and 4) DaTscan quantitative analysis using semi-automated processing to provide standardized and harmonized region-to-background and z-score data. The Neuroimaging Core aims are to: 1) establish and maintain harmonized MRI and DaTscan SPECT acquisition protocols at the participating sites, 2) operate a standardized quality control program for MRI and DaTscan, including ongoing image quality monitoring, rating and maintenance, and 3) supply processed cross-sectional and longitudinal data on serial MRIs and DaTscans for the Project focused on predicting phenoconversion, and share these data with the research community. This latter aim includes providing cross-sectional and longitudinal data to the Laboratory of Neuroimaging (LONI) for sharing with outside investigators. All images will be anonymized and directly downloadable from the LONI website. Language will be developed on the NAPS2 and LONI websites to guide outside investigators interested in these data. This clinical dataset will be freely downloadable along with the images for researchers who do not require genetic information for their analyses.

摘要：NAPS2神经成像核心 北美前驱综合征核糖核病联合会的神经影像核心， 第2阶段(NAPS2)将确保应用最先进的技术，并确保创新分析 使用了各种技术。神经成像核心将由脑成像领域的领导者在 神经退行性疾病，具有丰富的经验，支持多站点项目的成像需求。 许多核心领导人曾与国家行动方案调查人员合作进行RBD和 联体核病。神经成像核心团队之前的经验和合作将确保 平稳过渡对NAPS2的映像支持。以往对RBD的影像研究很少，而且一般 进行小规模、回溯性或单站点调查。我们提供初步数据来支持所有 将在协议中使用的成像模式，并展示方法的可靠性 建议。我们将前瞻性地收集和评估300多个样本中的多模式MRI和DaTcan成像数据 在纵向两个时间点，以创新的方法支持项目和 把场地向前推进。这个核心有几个创新方面，包括使用：1)多外壳和 合理的多波段成像采集协议采集高分辨率dMRI和rS-fMRI数据 采集时间，跨多个站点协调，2)用多回波梯度回波定量铁负荷 (GRE)MRI使用定量磁化率图和R2*松弛计量学，3)神经黑色素的定量 磁化传递对比法研究蓝斑和黑质致密部的体积 神经黑色素敏感核磁共振(NM-MRI)方法，具有自动图像处理和高重复性， 和4)使用半自动处理的DaTcan定量分析，以提供标准化和 协调区域到背景和z分数数据。神经成像的核心目标是：1)建立和 在参与地点维护统一的MRI和DaTscan SPECT采集协议，2)运营 MRI和DaTcan的标准化质量控制程序，包括持续的图像质量监测、评级 和维护，以及3)提供关于系列磁共振成像和DAT扫描的经处理的横断面和纵向数据 该项目的重点是预测表观转化，并与研究界分享这些数据。 后一目标包括向神经成像实验室提供横截面和纵向数据 (LONI)与外部调查人员分享。所有图像都将被匿名，并可直接从 Loni网站。将在NAPS2和LONI网站上开发语言，以指导外部 调查人员对这些数据感兴趣。该临床数据集将可随图像一起免费下载 对于那些在分析中不需要遗传信息的研究人员。